Pricing Log in Create free account

Tarsus Pharmaceuticals, Inc. (TARS) vs Viking Therapeutics, Inc. (VKTX)

Tarsus Pharmaceuticals, Inc. and Viking Therapeutics, Inc. are both Biotechnology companies. Tarsus Pharmaceuticals, Inc. and Viking Therapeutics, Inc. are of similar size ($3.5B and $3.5B). Viking Therapeutics, Inc. has the higher net margin (0.00% vs −7.67%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, Tarsus Pharmaceuticals, Inc. leads on 7 and Viking Therapeutics, Inc. on 6.

Valuation

Metric TARS VKTX Biotechnology median
P/E n/m n/m 8.50
P/S 4.87 n/m 9.71
P/B 8.52 7.17 2.13
Price to free cash flow 62.84 n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 4.25 n/m 9.21
Earnings yield (1.60%) (18.51%) (33.15%)
Free cash flow yield 1.59% (14.30%) (25.50%)

Profitability

Metric TARS VKTX Biotechnology median
Gross margin 93.28% 0.00% 65.16%
Operating margin (8.00%) 0.00% 0.00%
Net margin (7.67%) 0.00% 0.00%
Free cash flow margin 9.24% 0.00% 0.00%
Return on equity (13.68%) (88.85%) (56.36%)
Return on assets (8.40%) (79.24%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric TARS VKTX Biotechnology median
Revenue growth (TTM) 105.17% — 6.02%
EPS growth (last fiscal year) 48.21% (215.84%) 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric TARS VKTX Biotechnology median
Debt to equity 0.21 0.00 0.00
Current ratio 3.20 4.72 4.72
Net debt to EBITDA 4.66 1.76 0.96

Dividend

Metric TARS VKTX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric TARS VKTX Biotechnology median
Market cap 3.50b 3.48b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack